Patents
Literature
27 results about "IDH1" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Isocitrate dehydrogenase 1 (NADP+), soluble is an enzyme that in humans is encoded by the IDH1 gene on chromosome 2. Isocitrate dehydrogenases catalyze the oxidative decarboxylation of isocitrate to 2-oxoglutarate. These enzymes belong to two distinct subclasses, one of which uses NAD⁺ as the electron acceptor and the other NADP⁺. Five isocitrate dehydrogenases have been reported: three NAD⁺-dependent isocitrate dehydrogenases, which localize to the mitochondrial matrix, and two NADP⁺-dependent isocitrate dehydrogenases, one of which is mitochondrial and the other predominantly cytosolic. Each NADP⁺-dependent isozyme is a homodimer. The protein encoded by this gene is the NADP⁺-dependent isocitrate dehydrogenase found in the cytoplasm and peroxisomes. It contains the PTS-1 peroxisomal targeting signal sequence. The presence of this enzyme in peroxisomes suggests roles in the regeneration of NADPH for intraperoxisomal reductions, such as the conversion of 2,4-dienoyl-CoAs to 3-enoyl-CoAs, as well as in peroxisomal reactions that consume 2-oxoglutarate, namely the alpha-hydroxylation of phytanic acid. The cytoplasmic enzyme serves a significant role in cytoplasmic NADPH production. Alternatively spliced transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Sep 2013]
Gene Idh1 conditional knockout mouse model and construction method and application of preeclampsia-induced heart injury animal model
The invention provides a construction method and application of a gene Idh1 conditional knockout mouse model and a preeclampsia heart injury animal model, and relates to the technical field of biology. According to the preeclampsia heart injury animal model, flox mice with conditional gene Idh1 knockout and mice with placental trophoblast specific expression Cre recombinase comate, PE-related phenotypes and typical symptoms of heart injury spontaneously appear in the double-positive pregnant mouse model, and the double-positive pregnant mouse model can be used for research of disease causes, diagnosis methods and drug research and development.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Colloidal gold immune test strip for intraoperative instant detection of IDH1 mutant protein as well as preparation method and application of colloidal gold immune test strip
The invention discloses a preparation method and application of a colloidal gold immunochromatography test strip for detecting IDH1 mutant protein, and belongs to the field of rapid immunodetection. The colloidal gold chromatography test strip comprises a bottom plate, a sample pad, a nitrocellulose membrane, a water absorption pad and colloidal gold, the nitrocellulose membrane is sequentially provided with a detection line T and a quality control line C in the flowing direction of a sample, the detection line T is coated with IDH1 mutant protein, and the quality control line C is coated with a second antibody corresponding to a monoclonal antibody of the IDH1 mutant protein. Clinical tumor tissue samples collected in real time in glioma resection surgery are treated, an object to be detected and an immune gold label are mixed, incubated and dropped in a test strip sample adding hole, and the object to be detected runs along the test strip under the driving of a buffer solution and generates visual color change. The test strip has the advantages of being rapid in reaction, easy and convenient to operate, convenient to carry, high in specificity and the like, makes up the blank of an IDH1 mutant protein concentration quantitative method, and has good clinical application value.
Owner:NANJING NORMAL UNIVERSITY
Method for detecting and analyzing related substances in IDH1 mutant inhibitor
The invention belongs to the technical field of chemical drug analysis and detection, and discloses a method for detecting and analyzing related substances in an IDH1 mutant inhibitor, an IDH1 mutant inhibitor sample is prepared into a test solution, high performance liquid chromatography is adopted for detection, and chromatographic conditions are as follows: octadecyl phenyl bonded silica gel is adopted as a filler of a chromatographic column; a mobile phase A is a diammonium hydrogen phosphate aqueous solution, a mobile phase B is acetonitrile, and gradient elution is carried out. According to the detection and analysis method, the related substances in the IDH1 mutant inhibitor can be detected, the specificity, the quantitation limit, the detection limit, the linear range, the repeatability, the accuracy, the durability and the like completely meet the standards, and meanwhile the detection and analysis method has high sensitivity and high precision and can be used for quantitative analysis of the related substances in the IDH1 mutant inhibitor.
Owner:KPC PHARM INC
Compositions and methods for targeting extracellular DNA
PCT designated stage expiredWO2024259297A2Polypeptide with localisation/targeting motifFusion with DNA-binding domainIDH1Disease
Provided herein are compositions and methods of zinc-finger polypeptides that can bind to a specific wild-type or mutant sequence of genes of interest, including KRAS, TP53, BRAF, PIK3CA, or IDH1, for disease diagnosis and treatment use.
Owner:CARIS SCIENCE INC
Preparation method of IDH1 mutant inhibitor
PendingCN119490460AThe technical scheme of the synthesis reaction is reasonableSimple processOrganic compound preparationOrganic chemistry methodsIDH1Propanoic acid
The invention belongs to the technical field of medicine preparation, and discloses a preparation method of an IDH1 mutant inhibitor, which comprises the following steps: by taking 3-nitro-4-fluorobenzaldehyde and triethyl phosphorylacetate as raw materials, carrying out HWE reaction, substitution reaction, hydrogenation pressurization reaction, cyclization reaction and hydrolysis reaction in sequence to obtain (R)-3-(1-(1, 2, 3, 4-tetrahydro-2H-1, 2, 4-tetrahydro-2H-1, 2, 4-tetrahydro-2H-1, 2, 4-tetrahydro-2H-1, 2, 4-tetrahydro-2H-1, 2, 4- The preparation method comprises the following steps: firstly, preparing (R)-3-(1-(1, 2, 3, 4-tetrahydronaphthalene-1-yl)-2-((4-trifluoromethoxy) phenyl) amino)-1H-benzo [d] imidazole-5-yl) propionic acid in a crystal form A, and then carrying out a crystal transformation process to prepare (R)-3-(1-(1, 2, 3, 4-tetrahydronaphthalene-1-yl)-2-((4-trifluoromethoxy) phenyl) amino)-1H-benzo [d] imidazole-5-yl) propionic acid in a crystal form B; wherein the crude product obtained by the HWE reaction is subjected to pulping treatment and impurity removal, and then is used for the reaction of the next step. Compared with a direct leaching mode, the crude product pulping mode has the advantages that impurities can be better removed, the purity of an intermediate product is improved, and the purity of the finally obtained target product is further improved.
Owner:KPC PHARM INC +1
The application of IDH1 inhibitors combined with PARP inhibitors
ActiveCN119868565BAntineoplastic agentsHeterocyclic compound active ingredientsIDH1Pharmacy medicine
The present invention discloses the use of an IDH1 inhibitor combined with a PARP inhibitor for anti-tumor purposes. This drug combination inhibits DNA damage repair in tumors by suppressing homologous recombination repair, increasing the sensitivity of BRCA1 / 2 wild-type tumors to PARP inhibitors, addressing PARP resistance. It also exhibits synergistic anti-tumor effects, providing a new approach and means for the effective treatment of ovarian cancer and promising clinical application prospects.
Owner:CHINA PHARM UNIV
Methods for detecting acute myeloid leukemia
PendingUS20250354218A1Microbiological testing/measurementImmunoglobulins against animals/humansIDH1Spliceosome
The present technology relates to methods for predicting the risk of acute myeloid leukemia (AML) in a subject prior to the onset of AML symptoms, and whether such a subject will benefit from treatment with an AML therapy. The methods disclosed herein are based on detecting the presence of mutations in the nucleic acid sequences of IDH1 / 2, TP53, DNMT3A, TET2, and spliceosome genes. Kits for use in practicing the methods are also provided.
Owner:CORNELL UNIVERSITY
Synthetic polyunsaturated fatty acid conjugated phospholipid yeast engineering bacteria, construction method and application thereof
ActiveCN121699770BIDH1Pyruvate synthesis
The present application relates to a kind of synthetic polyunsaturated fatty acid binding phospholipid yeast engineering bacteria and construction method and application, belong to microbial engineering technical field, the engineering bacteria is with Yarrowia lipolytica as bottom cell, knock out the Mhy1, Iro1, IDH1, CEX1 gene in its genome for generating mycelium, synthesis of triglyceride, citric acid metabolism, citric acid efflux;Phospholipid synthesis, pyruvate synthesis, polyunsaturated fatty acid synthesis and acyltransferase CDS1, OPI3, Mce2, LplA, △9Elo, △8Des, △5Des, △17Des, △5Elo, △15Des, LPCAT3 gene are sequentially connected together, as an expression module is integrated in the URA site of genome.The yeast engineering bacteria of the present application obtains polyunsaturated fatty acid binding phospholipid in one step efficiently, and phospholipid yield is 151.19 mg / g, and in binding fatty acid, EPA content is 13.2%.
Owner:YELLOW SEA FISHERIES RES INST CHINESE ACAD OF FISHERIES SCI
Compound for targeted degradation of mIDH1 protein and application thereof
PendingCN121930304AAddressing drug resistancerecovery functionOrganic active ingredientsDipeptide ingredientsIDH1Chemical compound
The invention relates to the technical field of medicines, in particular to a compound for targeted degradation of mIDH1 protein and application of the compound. According to the invention, a series of compounds with a 'PL-Linker-EL' ternary structure are creatively designed and synthesized, so that a fundamental treatment strategy breakthrough from traditional'protein function inhibition 'to direct'pathogenic protein removal' is realized. The compound can be combined with mutant IDH1 (mIDH1) protein and E3 ubiquitin ligase in a targeted manner at the same time, and then mIDH1 is induced to be subjected to ubiquitination modification and is thoroughly degraded through a proteasome way, so that the problem of drug resistance caused by mutation is expected to be overcome, and a new treatment choice is provided for patients who are invalid or relapse in the existing therapy.
Owner:TONGREN POLYTECHNIC COLLEGE
How to identify patients who are likely to benefit from telomerase inhibitor treatment
For example, to provide a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors such as imetelstat. [Solution] This disclosure provides a method for identifying or selecting patients who are most likely to benefit from treatment with telomerase inhibitors, such as imetelstat, by testing for high molecular weight risk (HMR) based on the absence of mutations in each of JAK2, CALR, and MPL, and / or the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1 / 2. These patients may have myelofibrosis. This disclosure also provides a method for treating myelofibrosis, the method of which includes identifying such patients.
Owner:GERON CORP
Recombinant yarrowia lipolytica strain with high itaconic acid yield as well as construction method and application of recombinant yarrowia lipolytica strain
The invention discloses a recombinant yarrowia lipolytica strain with high yield of itaconic acid and a construction method and application thereof, and belongs to the field of strain cultivation, the recombinant yarrowia lipolytica strain is obtained by metabolism reconstruction of a wild type yarrowia lipolytica strain, a cis-aconitic acid decarboxylase gene cadA derived from Aspergillus terreus ATCC20542 is inserted into a genome, and a stable expression cassette is formed through a TEF1 promoter and a CYC1 terminator; a CIT1 gene front-end signal peptide is fused at the N end of the cadA to realize directional expression of mitochondria; iDH1, ACL1 and ADH1 genes are knocked out at the same time; cIT1 and ACO1 genes are overexpressed to enhance the flux of citric acid in the direction of cis-aconitic acid; and the noxE gene of Lactococcus lactis is introduced to regulate the balance of NADH (Nicotinamide Adenine Dinucleotide Hormone) in the cell. The strain is fermented for 72 hours under the conditions that glucose is used as a carbon source, the temperature is 30 DEG C and the pH value is 5.5-6.0, and the yield of itaconic acid can reach 12 g / L or above. According to the construction method, gene knockout and homologous recombination integration are realized by adopting CRISPR-Cas9, and a target strain is obtained after screening and verification. The method is used for preparing degradable polymers, plasticizers and medical intermediates. The method has the beneficial effects that the itaconic acid yield and metabolism efficiency are improved.
Owner:SHUANGHE (BEIJING) BIOTECHNOLOGY CO LTD
Methods of identifying patients who are likely to benefit from telomerase inhibitor treatment
The present invention provides methods for identifying or selecting a patient who is most likely to benefit from treatment with a telomerase inhibitor, such as imerostat, by performing a test on the patient that each of JAK2, CALR and MPL does not mutate; and / or a macromolecular risk (HMR) determined based on the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2 and IDH1 / 2. The patient may have myelofibrosis. The invention also provides methods of treating myelofibrosis, including identifying such patients.
Owner:GERON CORP
Application of IDH1 gene in porcine ovarian granular cells
The invention relates to an application of an IDH1 gene in porcine ovarian granular cells, in particular to an application in regulating proliferation and apoptosis of the porcine ovarian granular cells and / or steroid hormone synthesis and / or reproductive performance related gene expression. According to the invention, porcine ovarian granular cells are taken as objects, and the expression of the IDH1 gene is regulated to verify that the IDH1 gene is taken as a key target spot for regulating and controlling the functions of the porcine ovarian granular cells so as to influence steroid hormone synthesis and cell proliferation and apoptosis processes. A new molecular target is provided for improving the reproductive performance of the sow, more reliable technical support is provided for regulating and controlling the ovarian function, and a new thought and technical guidance are provided for mechanism research of reproductive diseases and preparation and development of related drugs.
Owner:HUNAN AGRI UNIV
Novel IDH1 mutant inhibitor and application thereof
The invention relates to a novel IDH1 mutant inhibitor and application thereof, and belongs to the technical field of biological medicine. The invention provides application of a compound Y0404481 in preparation of an IDH1 mutant inhibitor. The chemical structure of the compound Y0404481 is shown as a formula (I) in the specification. According to the present invention, the research results show that the compound Y0404481 has strong inhibition activity on the IDH1 R132C mutation of HT1080 cells and the IDH1 R132C / S280 F mutation of the HT1080 cells, and has low toxicity on LO2 cells; the inhibitory activity of the compound Y0404481 on IDH1 R132C mutation of HT1080 cells and IDH1 R132C / S280 F mutation of HT1080 cells is improved by 50 times and 24 times compared with that of a positive drug DS1001b, and the compound Y0404481 has good activity and low toxicity at the cellular level.
Owner:SHAANXI UNIV OF CHINESE MEDICINE
Oxazolone-substituted pyrimidinamine compound, preparation method therefor, pharmaceutical composition thereof and use thereof
PCT designated stageWO2025180420A1Organic active ingredientsOrganic chemistryIDH1Pharmaceutical drug
Provided in the present invention are an oxazolone-substituted pyrimidinamine compound, a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Specifically, provided in the present invention are a compound having a structure as shown in general formula (I), and a racemate, R-isomer, S-isomer, pharmaceutically acceptable salt thereof, or a mixture thereof. The compound has good IDH1 inhibitory activity, and therefore can be used for treating, preventing and relieving diseases related to IDH1 enzyme, especially for treating malignant tumors or other related diseases caused by IDH1 enzyme mutation.
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Cocrystal of an IDH1 inhibitor, process of preparation thereof, pharmaceutical compositions thereof, and methods of treatment involving the same
PCT designated stage expiredWO2025027075A1Organic active ingredientsOrganic chemistry methodsIDH1Glutaric acid
Provided is a cocrystal of a compound (I) and glutaric acid useful for treating cancer and a process for the preparation thereof, pharmaceutical compositions thereof and use for the treatment of cancer comprising administering the cocrystal described herein to a patient in need thereof.
Owner:LES LAB SERVIER SA
WT-IDH1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma
Disclosed are methods of treating diseases or disorders associated with the expression of wild type isocitrate dehydrogenase 1 (IDH1). The disclosed methods may be utilized to treat diseases or disorders associated with cell proliferation, including cancer.
Owner:NORTHWESTERN UNIV
Antibody of crotonylated isocitrate dehydrogenase 1 as well as preparation method and application thereof
The invention relates to an antibody of crotonylated isocitrate dehydrogenase 1 as well as a preparation method and application thereof, and particularly provides a polyclonal antibody, the polyclonal antibody is obtained by immunizing an animal through IDH1 crotonylated antigen epitope peptide, the specific site of the antigen epitope peptide is crotonylated, the high-titer antibody can be prepared, and the antibody can be used for preparing the isocitrate dehydrogenase 1. Crotonylation modification of IDH1 in a clinical specimen can be recognized with high specificity, and the compound can be used for immunoblotting and immunohistochemical research of cell / tissue specimens and diagnosis of IDH1 related diseases.
Owner:BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
Application of IDH1 inhibitor in preparation of medicine for treating central nervous system demyelination disease
The invention discloses application of an IDH1 inhibitor in preparation of a medicine for treating a central nervous system demyelination disease. Research finds that the IDH1 inhibitor can significantly improve the body weight and neurological function clinical score of a model mouse and alleviate demyelination. Therefore, the IDH1 inhibitor disclosed by the invention can be used for treating the central nervous system demyelination disease and has an important clinical application value.
Owner:THE SECOND HOSPITAL OF HEBEI MEDICAL UNIV +1
Oxazolone-substituted pyrimidinamine compound, and preparation method, pharmaceutical composition and application thereof
The invention provides an oxazolone-substituted pyrimidinamine compound as well as a preparation method, a pharmaceutical composition and application thereof, and particularly provides a compound with a structure as shown in a general formula I, and a racemate, an R-isomer, an S-isomer, a pharmaceutically acceptable salt or a mixture of the racemate, the R-isomer, the S-isomer and the pharmaceutically acceptable salt thereof. The compound has good IDH1 inhibitory activity, so that the compound can be used for treating, preventing and relieving diseases related to IDH1 enzyme, especially malignant tumors or other related diseases caused by IDH1 enzyme mutation. # imgabs0 #
Owner:SHANGHAI INSTITUTE OF MATERIA MEDICA CHINESE ACADEMY OF SCIENCES
Salt form and crystal form of mutant IDH1 inhibitor and preparation method therefor
Owner:KPC PHARM INC
Compositions and methods for targeting extracellular DNA
PCT designated stage expiredWO2024259297A3Polypeptide with localisation/targeting motifFusion with DNA-binding domainIDH1Disease
Provided herein are compositions and methods of zinc-finger polypeptides that can bind to a specific wild-type or mutant sequence of genes of interest, including KRAS, TP53, BRAF, PIK3CA, or IDH1, for disease diagnosis and treatment use.
Owner:CARIS SCIENCE INC
Methods of identifying patients likely to benefit from treatment with telomerase inhibitor
To provide methods of identifying or selecting a patient most likely to benefit from treatment with a telomerase inhibitor, such as imetelstat.SOLUTION: This disclosure provides methods of identifying or selecting a patient most likely to benefit from treatment with a telomerase inhibitor, such as imetelstat, by testing the patient for: a lack of a mutation in each of JAK2, CALR, and MPL; and / or a high-molecular risk (HMR), based on the presence of a mutation in at least one of the following genes: ASXL1, EZH2, SRSF2, and IDH1 / 2. The patient may suffer from myelofibrosis. The disclosure also provides methods of treating myelofibrosis, which include identifying such patients.SELECTED DRAWING: None
Owner:GERON CORP
Use of kavain C in the preparation of IDH1 inhibitors
The present invention relates to the fields of clinical medicine and biopharmaceutical technology, and specifically relates to the application of flavokawain C in inhibiting IDH1 mutant tumor cells in the treatment of tumors. Through a large number of experimental studies, the present invention has found that flavokawain C has the function of selectively inhibiting IDH1 mutant tumor cells, can significantly reduce the 2-HG level in IDH1 mutant cells, and has no obvious toxic and side effects on normal cells. Based on the above clinical problems, the present invention aims to explore the application of flavokawain C compound as an IDH1 covalent inhibitor in anti-IDH1 mutant tumors, in order to provide new options and more effective solutions for the treatment of IDH1 mutant tumors.
Owner:XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI
Application of kavaenin C in preparation of IDH1 inhibitor
The invention relates to the technical field of clinical medicine and biological pharmacy, in particular to application of Flavokawain C in inhibiting IDH1 mutant tumor cells in tumor treatment. A large number of experimental studies show that the Flavokawain C has the function of selectively inhibiting IDH1 mutant tumor cells, can significantly reduce the 2-HG level in the IDH1 mutant cells, and has no obvious toxic or side effect on normal cells. Based on the clinical problems, the invention aims to explore the application of the Flavokawain C compound as an IDH1 covalent inhibitor in anti-IDH1 mutant tumors, so as to provide a new choice and a more effective solution for the treatment of the IDH1 mutant tumors.
Owner:XIYUAN HOSPITAL OF CHINA ACAD OF CHINESE MEDICAL SCI
